Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 1
---
. Shareholders attending the Special Meeting virtually will be afforded the same rights and opportunities to participate as they would receive at an in-person meeting. We believe that holding the Special Meeting as a completely virtual meeting will enable us to avoid the costs and complexities associated with meetings held in a hybrid format while
preserving a format that encourages U.S. and Canadian Shareholder inclusion and participation. In addition, with a view to ensure that all Shareholders will have equal opportunities to participate and vote at the Special Meeting from wherever they
may physically be located on January 16, 2026, we have updated certain of our disclosures to specify how Shareholders can make or comment on motions or raise points of order through our virtual Special Meeting web platform. We encourage you to
attend the Special Meeting online and participate. We recommend that you log in a few minutes before 10:00 a.m. (Montreal time) on January 16, 2026 to ensure you are logged in when the Special Meeting starts. Additional registration and
participation information appears in the enclosed proxy statement and management information circular (“Circular and Proxy Statement”).

At the Special Meeting, the Shareholders will be asked to consider and, if thought advisable, to pass, with or without variation, (i) a
special resolution (the “Arrangement Resolution”), the full text of which is set forth in Annex D to the accompanying Circular and Proxy Statement, to approve an arrangement (the “Arrangement”) under Chapter XVI
– Division II of the Business Corporations Act (Québec) (the “QBCA”) involving the Company, XenoTherapeutics, Inc. (the “Parent”), Xeno Acquisition Corp. (the “Purchaser”),
and XOMA Royalty Corporation (“XRC”) pursuant to an arrangement agreement dated November 14, 2025 (the “Agreement”) and the plan of arrangement (“Plan of Arrangement”) appended as Annex E
to the Circular and Proxy Statement, (ii) an ordinary resolution to approve, on an advisory and nonbinding basis, the compensation to be paid or become payable to the Company’s named executive officers that is based on or otherwise
relates to the Arrangement (the “Compensation Resolution”), and (iii) in the event that the Arrangement Resolution is not approved or the Arrangement is otherwise terminated, a special resolution pursuant to Section 308
of the QBCA to approve the voluntary liquidation (the “Liquidation”) and dissolution of the Company (the